| Literature DB >> 35668349 |
Alana R Cuthbert1,2, Lynne C Giles3, Gary Glonek4, Lisa M Kalisch Ellett5, Nicole L Pratt5.
Abstract
BACKGROUND: There is increasing interest in the development and use of clinical prediction models, but a lack of evidence-supported guidance on the merits of different modelling approaches. This is especially true for time-to-event outcomes, where limited studies have compared the vast number of modelling approaches available. This study compares prediction accuracy and variable importance measures for four modelling approaches in prediction of time-to-revision surgery following total knee arthroplasty (TKA) and total hip arthroplasty (THA).Entities:
Keywords: Flexible parametric survival model; Hip replacement; Knee replacement; Machine learning; Parametric survival model; Prediction model; Random survival forest; Time-to-event data
Mesh:
Substances:
Year: 2022 PMID: 35668349 PMCID: PMC9172144 DOI: 10.1186/s12874-022-01644-3
Source DB: PubMed Journal: BMC Med Res Methodol ISSN: 1471-2288 Impact factor: 4.612
Demographics, comorbid conditions and prosthesis use in all patients undergoing TKA and for those revised within 8 years of surgery
| Variable | All TKA | Revised |
|---|---|---|
| Median (IQR) age in years | 72 (67-78) | 70 (64-75) |
| N (%) female | 195,668 (60.8) | 5659 (57.6) |
| N (%) cemented femoral | 188,734 (58.6) | 5438 (55.4) |
| N (%) cemented tibial | 259,187 (80.5) | 7344 (74.8) |
| N (%) patella used | 164,333 (51) | 3916 (39.9) |
| N (%) fixed bearing | 257,008 (79.8) | 7202 (73.3) |
| N (%) minimally stabilised | 234,827 (72.9) | 6669 (67.9) |
| N (%) cross-linked polyethylene | 107,456 (33.4) | 2080 (21.2) |
| N (%) computer navigated | 60,164 (18.7) | 1551 (15.8) |
| N (%) anticoagulants | 42,398 (13.2) | 1281 (13) |
| N (%) antiplatelet medications | 64,011 (19.9) | 2091 (21.3) |
| N (%) anxiety | 34,863 (10.8) | 1462 (14.9) |
| N (%) Arrhythmia | 18,373 (5.7) | 568 (5.8) |
| N (%) congestive heart failure | 25,281 (7.9) | 833 (8.5) |
| N (%) depression | 83,445 (25.9) | 3165 (32.2) |
| N (%) diabetes | 47,041 (14.6) | 1442 (14.7) |
| N (%) Gastro-oesophageal reflux disease | 156,820 (48.7) | 5058 (51.5) |
| N (%) glaucoma | 20,382 (6.3) | 527 (5.4) |
| N (%) gout | 30,540 (9.5) | 997 (10.2) |
| N (%) hyperlipidaemia | 160,478 (49.8) | 4817 (49.1) |
| N (%) hypertension | 181,127 (56.3) | 5325 (54.2) |
| N (%) hypothyroidism | 33,546 (10.4) | 1053 (10.7) |
| N (%) ischaemic heart disease (angina) | 21,925 (6.8) | 826 (8.4) |
| N (%) ischaemic heart disease (hypertension) | 117,801 (36.6) | 3399 (34.6) |
| N (%) osteoporosis/Paget’s | 30,706 (9.5) | 844 (8.6) |
| N (%) pain | 151,805 (47.2) | 5514 (56.2) |
| N (%) inflammation pain | 176,883 (54.9) | 5949 (60.6) |
| N (%) chronic airways disease | 71,122 (22.1) | 2373 (24.2) |
| N (%) steroid responsive | 54,271 (16.9) | 1906 (19.4) |
Demographics, comorbid conditions and prosthesis use in all patients undergoing THA and for those revised within 8 years of surgery
| Variable | All THA | Revised |
|---|---|---|
| Median (IQR) age in years | 73 (68-79) | 73 (67-78) |
| N (%) female | 90,153 (59.7) | 2498 (56.6) |
| N (%) cemented femoral | 66,537 (44) | 1534 (34.7) |
| N (%) bearing surface | ||
| Ceramic/ceramic | 28,886 (19.1) | 1036 (23.5) |
| Ceramic/cross-linked polyethylene | 27,249 (18) | 698 (15.8) |
| Metal/cross-linked polyethylene | 94,978 (62.9) | 2681 (60.7) |
| N (%) head size | ||
| ≤ 28 mm | 29,724 (19.7) | 995 (22.5) |
| 32 mm | 64,854 (42.9) | 1761 (39.9) |
| 36 mm | 53,376 (35.3) | 1558 (35.3) |
| ≥ 40 mm | 3159 (2.1) | 101 (2.3) |
| N (%) anticoagulants | 20,990 (13.9) | 658 (14.9) |
| N (%) antiplatelet medications | 27,645 (18.3) | 899 (20.4) |
| N (%) anxiety | 16,146 (10.7) | 627 (14.2) |
| N (%) arrhythmia | 9092 (6) | 290 (6.6) |
| N (%) congestive heart failure | 11,708 (7.7) | 410 (9.3) |
| N (%) depression | 37,159 (24.6) | 1402 (31.8) |
| N (%) diabetes | 16,689 (11) | 494 (11.2) |
| N (%) Gastro-oesophageal reflux disease | 65,911 (43.6) | 2194 (49.7) |
| N (%) glaucoma | 9824 (6.5) | 286 (6.5) |
| N (%) gout | 11,325 (7.5) | 372 (8.4) |
| N (%) hyperlipidaemia | 70,365 (46.6) | 1990 (45.1) |
| N (%) hypertension | 78,101 (51.7) | 2270 (51.4) |
| N (%) hypothyroidism | 14,282 (9.5) | 430 (9.7) |
| N (%) ischaemic heart disease (angina) | 9576 (6.3) | 309 (7) |
| N (%) ischaemic heart disease (hypertension) | 50,495 (33.4) | 1512 (34.2) |
| N (%) osteoporosis/Paget’s | 15,157 (10) | 501 (11.3) |
| N (%) pain | 82,787 (54.8) | 2714 (61.5) |
| N (%) inflammation pain | 83,078 (55) | 2714 (61.5) |
| N (%) chronic airways disease | 29,633 (19.6) | 967 (21.9) |
| N (%) steroid responsive | 22,730 (15) | 805 (18.2) |
Fig. 1a Cumulative incidence of revision of TKA over 8 years. b Baseline hazard of TKA revision over 8 years. c Cumulative incidence of revision of THA over 8 years. d Baseline hazard of THA revision over 8 years. Shading indicates 95% confidence intervals
Performance metrics for predicting revision of TKA using Cox, Weibull parametric, flexible parametric, and random survival forest models
| TKA | |||
|---|---|---|---|
| Modelling Approach | c-index | Integrated calibration index (× 100) | Integrated Index of Prediction Accuracy |
| Cox | 0.643 (0.641, 0.645) | 0.16 (0.15, 0.18) | 0.056 (0.054, 0.057) |
| Weibull | 0.642 (0.641, 0.644) | 0.17 (0.16, 0.19) | 0.054 (0.053, 0.056) |
| Flexible parametric | 0.643 (0.641, 0.645) | 0.17 (0.15, 0.18) | 0.056 (0.054, 0.057) |
| Random survival forest | 0.643 (0.642, 0.645) | 0.27 (0.25, 0.29) | 0.055 (0.054, 0.056) |
Performance metrics for predicting revision of THA using Cox, Weibull parametric, flexible parametric, and random survival forest models
| THA | |||
|---|---|---|---|
| c-index | Integrated calibration index (×100) | Integrated Index of Prediction Accuracy | |
| Cox | 0.591 (0.589, 0.594) | 0.27 (0.25, 0.3) | 0.029 (0.027, 0.03) |
| Weibull | 0.591 (0.588, 0.594) | 0.29 (0.26, 0.31) | 0.028 (0.026, 0.029) |
| Flexible parametric | 0.591 (0.588, 0.594) | 0.28 (0.25, 0.3) | 0.029 (0.027, 0.030) |
| Random survival forest | 0.59 (0.587, 0.592) | 0.28 (0.25, 0.3) | 0.027 (0.025, 0.028) |
Fig. 2The calibration of models predicting eight-year risk of revision are compared using smoothed calibration curves, with black diagonal line denoting line of perfect calibration for a TKA and b THA
Fig. 3The Index of Prediction Accuracy is used to compare prediction accuracy of Cox, Weibull, flexible parametric and random survival forest for prediction of revision over eight-year time period for a TKA and b THA
Ranked importance of variables from backward elimination in Cox model compared to minimal depth from random survival forest, for prediction of TKA revision. Variables are displayed in decreasing order of importance
| Bootstrap backwards elimination in Cox model (95% CI) | Minimal depth from random survival forest (95% CI) | ||
|---|---|---|---|
| Age | 1 (1,1) | Age | 1.54 (1.45,1.64) |
| Pain | 2.26 (2.21,2.3) | Pain | 1.91 (1.8,2.02) |
| Patella usage | 2.92 (2.86,2.97) | Patella usage | 2.04 (1.93,2.15) |
| Stability | 4.39 (4.34,4.44) | Depression | 2.2 (2.08,2.32) |
| Bearing surface | 4.51 (4.43,4.59) | Bearing surface | 2.46 (2.34,2.58) |
| Depression | 6.22 (6.17,6.28) | Stability | 2.79 (2.68,2.9) |
| Sex | 7.39 (7.32,7.46) | Mobility | 3.05 (2.91,3.18) |
| Tibial cement | 8.8 (8.62,8.98) | Anxiety | 3.05 (2.91,3.19) |
| Anxiety | 10.6 (10.44,10.77) | Sex | 3.24 (3.13,3.35) |
| Ischaemic heart disease angina | 10.68 (10.48,10.87) | Tibial cement | 3.49 (3.36,3.62) |
| Mobility | 10.77 (10.6,10.95) | Inflammation pain | 4.2 (4.07,4.33) |
| Gastro-oesophageal reflux disease | 11.02 (10.81,11.23) | Ischaemic heart disease angina | 4.2 (4.09,4.32) |
| Steroid responsive diseases | 12.48 (12.27,12.7) | Steroid responsive diseases | 4.23 (4.11,4.35) |
| Computer navigation | 16.48 (16.22,16.74) | Gastro-oesophageal reflux disease | 4.28 (4.15,4.41) |
| congestive heart failure | 16.89 (16.5,17.28) | Hypertension | 4.47 (4.35,4.6) |
| Arrhythmia | 17.1 (16.74,17.46) | Ischaemic heart disease hypertension | 4.68 (4.56,4.8) |
| Ischaemic heart disease hypertension | 18.62 (18.29,18.95) | Computer navigation | 4.73 (4.62,4.83) |
| Hypothyroidism | 19.16 (18.82,19.5) | congestive heart failure | 4.74 (4.63,4.84) |
| Hypertension | 19.39 (19.02,19.76) | Gout | 4.74 (4.64,4.84) |
| Osteoporosis/Paget’s | 19.88 (19.53,20.23) | Chronic Airways Disease | 4.78 (4.66,4.9) |
| Anticoagulants | 21.74 (21.37,22.12) | Femoral cement | 4.86 (4.74,4.98) |
| Inflammation pain | 22.09 (21.76,22.42) | Glaucoma | 4.93 (4.81,5.05) |
| Chronic Airways Disease | 22.96 (22.61,23.31) | Anticoagulants | 4.93 (4.82,5.04) |
| Diabetes | 23.9 (23.58,24.22) | Osteoporosis/Paget’s | 5.1 (4.99,5.21) |
| Hyperlipidaemia | 24.12 (23.82,24.41) | Arrhythmia | 5.11 (5,5.21) |
| Antiplatelet medication | 24.28 (23.96,24.6) | Diabetes | 5.17 (5.07,5.27) |
| Gout | 24.86 (24.59,25.14) | Antiplatelet medication | 5.18 (5.07,5.29) |
| Glaucoma | 25.23 (24.95,25.52) | Hypothyroidism | 5.19 (5.1,5.29) |
| Femoral cement | 25.24 (24.97,25.51) | Hyperlipidaemia | 5.26 (5.16,5.36 |
Ranked importance of variables from backward elimination in Cox model compared to minimal depth from random survival forest, for prediction of THA revision. Variables are displayed in decreasing order of importance
| Bootstrap backwards elimination in Cox model (95% CI) | Minimal depth from random survival forest (95% CI) | ||
|---|---|---|---|
| Femoral cement | 1.46 (1.43,1.49) | Femoral cement | 0.66 (0.62,0.7) |
| Depression | 1.92 (1.87,1.98) | Depression | 0.99 (0.93,1.04) |
| Pain | 2.82 (2.76,2.89) | Pain | 1.5 (1.44,1.55) |
| Gastro-oesophageal reflux disease | 5.33 (5.19,5.46) | Gastro-oesophageal reflux disease | 2.44 (2.36,2.51) |
| Sex | 5.58 (5.49,5.67) | Sex | 2.7 (2.65,2.76) |
| Age | 7.49 (7.32,7.67) | Steroid responsive diseases | 2.77 (2.69,2.85) |
| Steroid responsive diseases | 8.29 (8.06,8.52) | Age | 3.1 (3.05,3.15) |
| Inflammation pain | 8.96 (8.79,9.13) | Congestive heart failure | 3.25 (3.18,3.32) |
| Anxiety | 9.74 (9.53,9.95) | Anxiety | 3.64 (3.55,3.74) |
| Congestive heart failure | 12.22 (11.93,12.5) | Bearing Surface | 3.74 (3.67,3.81) |
| Osteoporosis/Paget’s | 12.22 (11.98,12.46) | Head size | 3.88 (3.83,3.94) |
| Head size | 12.23 (11.97,12.49) | Osteoporosis/Paget’s | 3.93 (3.84,4.02) |
| Bearing surface | 12.32 (12.1,12.55) | Gout | 4.18 (4.1,4.26) |
| Hyperlipidaemia | 12.37 (12.19,12.54) | Inflammation pain | 4.32 (4.23,4.41) |
| Anticoagulant | 15.47 (15.18,15.76) | Acetabular cement | 4.33 (4.26,4.41) |
| Hypothyroidism | 16.74 (16.48,17) | Hyperlipidaemia | 4.6 (4.51,4.69) |
| Chronic Airways Disease | 17.61 (17.34,17.88) | Chronic Airways Disease | 4.78 (4.69,4.87) |
| Gout | 19.13 (18.86,19.4) | Anticoagulants | 4.95 (4.85,5.04) |
| Arrhythmia | 19.92 (19.64,20.2) | Arrhythmia | 5.05 (4.95,5.15) |
| Ischaemic heart disease hypertension | 20 (19.76,20.23) | Hypothyroidism | 5.28 (5.19,5.38) |
| Antiplatelet medications | 21.3 (21.09,21.52) | Ischaemic heart disease angina | 5.32 (5.22,5.43) |
| Glaucoma | 21.4 (21.2,21.6) | Hypertension | 5.48 (5.38,5.58) |
| Diabetes | 21.53 (21.33,21.74) | Ischaemic heart disease hypertension | 5.55 (5.46,5.64) |
| Ischaemic heart disease angina | 21.62 (21.42,21.82) | Antiplatelet medications | 5.57 (5.47,5.67) |
| Acetabular cement | 21.64 (21.45,21.84) | Diabetes | 5.74 (5.64,5.85) |
| Hypertension | 21.69 (21.48,21.89) | Glaucoma | 6.11 (6,6.21) |